

# Livius Penter

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6730930/publications.pdf>

Version: 2024-02-01

21  
papers

1,421  
citations

1040056

9  
h-index

794594

19  
g-index

21  
all docs

21  
docs citations

21  
times ranked

3718  
citing authors

#	ARTICLE	IF	CITATIONS
1	Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 3356-3366.	7.0	13
2	Rapid single-cell identification of Epstein-Barr virus-specific T-cell receptors for cellular therapy. <i>Cytotherapy</i> , 2022, 24, 818-826.	0.7	5
3	Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation. <i>Blood</i> , 2021, 137, 3212-3217.	1.4	24
4	Longitudinal Single-Cell Dynamics of Chromatin Accessibility and Mitochondrial Mutations in Chronic Lymphocytic Leukemia Mirror Disease History. <i>Cancer Discovery</i> , 2021, 11, 3048-3063.	9.4	31
5	Coevolving JAK2V617F+relapsed AML and donor T cells with PD-1 blockade after stem cell transplantation: an index case. <i>Blood Advances</i> , 2021, 5, 4701-4709.	5.2	12
6	Dissecting Richter's Syndrome in a Multiplexed CRISPR-Based Mouse Model Reveals Key Changes in MYC, Interferon and BCR Signaling Underlying Transformation. <i>Blood</i> , 2021, 138, 251-251.	1.4	1
7	Mitochondrial DNA Mutations Distinguish Individual Donor- and Recipient-Derived Immune Cells Following Matched Unrelated Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2021, 138, 1689-1689.	1.4	2
8	Natural Barcodes for Longitudinal Single Cell Tracking of Leukemic and Immune Cell Dynamics. <i>Frontiers in Immunology</i> , 2021, 12, 788891.	4.8	12
9	Personal tumor antigens in blood malignancies: genomics-directed identification and targeting. <i>Journal of Clinical Investigation</i> , 2020, 130, 1595-1607.	8.2	10
10	Safety and Efficacy of Decitabine Plus Ipilimumab in Relapsed or Refractory MDS/AML in the Post-BMT or Transplant Naïve Settings. <i>Blood</i> , 2020, 136, 15-17.	1.4	9
11	Clonally Expanded Bone Marrow T Cells Show Effector Differentiation and Rarely Recognize Disease-Associated Antigens in Multiple Myeloma. <i>Blood</i> , 2020, 136, 7-7.	1.4	0
12	Local and Systemic Effects of Immune Checkpoint Blockade on Relapsed Myeloid Malignancies Following Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2020, 136, 34-35.	1.4	1
13	Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition). <i>European Journal of Immunology</i> , 2019, 49, 1457-1973.	2.9	766
14	Localization-associated immune phenotypes of clonally expanded tumor-infiltrating T cells and distribution of their target antigens in rectal cancer. <i>Oncolmmunology</i> , 2019, 8, e1586409.	4.6	20
15	FACS single cell index sorting is highly reliable and determines immune phenotypes of clonally expanded T cells. <i>European Journal of Immunology</i> , 2018, 48, 1248-1250.	2.9	23
16	Abstract 4679: Rectal cancer-infiltrating T cells show clonal expansion associated with spatially restricted tolerogenic phenotypes. , 2018, , .		0
17	Clonal Expansion and Interrelatedness of Distinct B-Lineage Compartments in Multiple Myeloma Bone Marrow. <i>Cancer Immunology Research</i> , 2017, 5, 744-754.	3.4	17
18	Allogeneic Stem Cell Transplantation (SCT) in Elderly Patients with AML and ALL: Chance of Cure?. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S197.	2.0	1

#	ARTICLE	IF	CITATIONS
19	A rapid screening system evaluates novel inhibitors of DNA methylation and suggests F-box proteins as potential therapeutic targets for high-risk neuroblastoma. Targeted Oncology, 2015, 10, 523-533.	3.6	16
20	Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia, 2015, 29, 2062-2068.	7.2	455
21	Treatment of Corticosteroid-Refractory Graft-Versus-Host Disease with Ruxolitinib in 95 Patients. Blood, 2015, 126, 858-858.	1.4	3